



Title	Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation
Author(s)	Fukushima, Kentaro; Kudo, Hayami; Oka, Kentaro et al.
Citation	Bone Marrow Transplantation. 2024, 59, p. 795-802
Version Type	VoR
URL	<a href="https://hdl.handle.net/11094/95019">https://hdl.handle.net/11094/95019</a>
rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
Note	

*The University of Osaka Institutional Knowledge Archive : OUKA*

<https://ir.library.osaka-u.ac.jp/>

The University of Osaka

## ARTICLE OPEN



# *Clostridium butyricum* MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation

Kentaro Fukushima<sup>1</sup>✉, Hayami Kudo<sup>2</sup>, Kentaro Oka<sup>2</sup>, Atsushi Hayashi<sup>2</sup>, Makoto Onizuka<sup>3</sup>, Shinsuke Kusakabe<sup>1</sup>, Akihisa Hino<sup>1</sup>, Motomichi Takahashi<sup>2</sup>, Kiyoshi Takeda<sup>4,5,6</sup>, Masaki Mori<sup>7</sup>, Kiyoshi Ando<sup>3</sup> and Naoki Hosen<sup>1,5,6</sup>

© The Author(s) 2024

In patients undergoing haematopoietic stem-cell transplantation (HSCT), the intestinal microbiota plays an important role in prognosis, transplant outcome, and complications such as graft-versus-host disease (GVHD). Our prior research revealed that patients undergoing HSCT substantially differed from healthy controls. In this retrospective study, we showed that administering *Clostridium butyricum* MIYAIRI 588 (CBM588) as a live biotherapeutic agent is associated with maintaining intestinal microbiota in the early post-HSCT period. Alpha diversity, which reflects species richness, declined considerably in patients who did not receive CBM588, whereas it remained consistent in those who received CBM588. In addition,  $\beta$ -diversity analysis revealed that CBM588 did not alter the gut microbiota structure at 7–21 days post-HSCT. Patients who developed GVHD showed structural changes in their microbiota from the pre-transplant period, which was noticeable on day 14 before developing GVHD. *Enterococcus* was significantly prevalent in patients with GVHD after HSCT, and the population of *Bacteroides* was maintained from the pre-HSCT period through to the post-HSCT period. Patients who received CBM588 exhibited a contrasting trend, with lower relative abundances of both genera *Enterococcus* and *Bacteroides*. These results suggest that preoperative treatment with CBM588 could potentially be beneficial in maintaining intestinal microbiota balance.

Bone Marrow Transplantation; <https://doi.org/10.1038/s41409-024-02250-1>

## INTRODUCTION

The intestinal microbiota plays a crucial role in maintaining human health by regulating digestion, metabolism, and immune function [1–3]. Haematopoietic stem cell transplantation (HSCT) is a curative therapy for various haematological malignancies and non-malignant disorders [4–6]. Innovations in amplicon sequencing technology, conditioning chemotherapy, HSCT, and subsequent antimicrobial treatment have been shown to significantly influence intestinal microbiota [7–10]. Time-dependent analyses of the intestinal microbiota before and after transplantation have shown that the stability of the intestinal microbiota positively influences prognosis not only during the peri-transplant period but also over the long term [11–13].

Recently, living organisms with clear effects on diseases have been designated as live biotherapeutic products (LBPs), a new classification that differs from conventional probiotics [14–16]. *Clostridium butyricum* MIYAIRI 588 (CBM588), a spore-forming anaerobic bacterium, is recognised and categorised as an LBP [17], and is used for the treatment and prevention of diarrhoea or constipation symptoms related to microbial dysbiosis in some

countries, particularly in Japan [18]. CBM588 also exhibits tolerance to various stress factors, such as low pH and antimicrobials; therefore, CBM588 is effective in treating and preventing antibiotic-associated diarrhoea in children by normalising the intestinal microbiota disturbed by antibiotics [19]. Administering CBM588 in mice improved the imbalance of microbial conditions caused by antibiotics [20]. Specifically, CBM588 increased *Bifidobacterium*, *Lactobacillus*, and *Lactococcus* abundance in the gut. Likewise, similar results were observed that *Bifidobacterium spp.* increased in patients with renal cell carcinoma who responded to CBM588 with immune-checkpoint inhibitor treatment [21]. Microbial treatment using probiotics, prebiotics, and faecal microbiota transplantation are associated with therapeutic efficacy in patients with HSCT [22–26]. However, the efficacy of microbial intervention approaches after HSCT is debatable, owing to a lack of knowledge regarding their safety and mechanism of action [27]. A randomised pilot study (NCT03922035) is currently underway to assess the safety and feasibility of CBM588 administration during the peri-transplant period and to compare the incidence and severity of adverse events [28].

<sup>1</sup>Department of Haematology and Oncology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan. <sup>2</sup>R&D Division, Central Research Institute, Miyarisan Pharmaceutical Co., Ltd., Saitama 331-0804, Japan. <sup>3</sup>Department of Hematology/Oncology, Tokai University School of Medicine, Isehara 259-1193, Japan. <sup>4</sup>Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan. <sup>5</sup>World Premier International Immunology Frontier Research Centre, Osaka University, Suita 565-0871, Japan. <sup>6</sup>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita 565-0871, Japan. <sup>7</sup>Faculty of Medicine, Tokai University School of Medicine, Isehara 259-1193, Japan.

✉email: kfkushi@bldon.med.osaka-u.ac.jp

Received: 16 September 2023 Revised: 8 February 2024 Accepted: 12 February 2024

Published online: 02 March 2024

In this study, we aimed to evaluate the effects of prophylactic CBM588 administration on the intestinal microbiota after HSCT by using 16S rRNA amplicon sequencing.

## MATERIALS AND METHODS

### Patients

This study was approved by the sites' institutional review boards and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. Forty patients who underwent allogeneic HSCT at Osaka or Tokai University Hospital between May 2006 and May 2017 were included. All enrolled patients were of Japanese ethnicity. Data collected for analysis included age at transplantation, sex, conditioning regimen, date and cause of death, and the incidence and severity of acute graft-versus-host disease (aGVHD). The definitions of myeloablative conditioning or reduced-intensity conditioning regimens were based on previous methodology, with slight modifications [29, 30]. The reliability of GVHD diagnosis in all patients was assessed using confidence levels defined by The Mount Sinai Acute GVHD International Consortium [31]. CBM588, known as Miya-BM (Miyarisan Pharmaceutical Co., Ltd., Tokyo, Japan), is an approved medication for improving digestive symptoms and is commonly used in Japan. Patients were administered 60 mg of oral CBM588 daily in addition to the usual postoperative antimicrobials.

### Collection of faecal samples

Baseline faecal samples were collected 7 days before HSCT, i.e., before initiation of HSCT conditioning regimens. Subsequently, we sequentially obtained one sample per week from the initiation of the conditioning regimen until 35 days after HSCT. Patients placed the faecal samples into disposable sterile faeces tubes (76 × 20 mm; Sarstedt, Nümbrecht, Germany), and the samples were preserved in RNAlater™ stabilisation solution (Thermo Fisher Scientific, Waltham, MA, USA) at −80 °C. Faecal samples were collected from all 40 patients. Patients whose samples were not accurately collected every 7 days were excluded. Patients were also excluded if their samples were unavailable within a two-day window either before or after each designated time point, namely −7, 0, 7, 14, 21, 28, and 35 days. Faecal samples (196) from a sub-cohort of 37 patients were analysed via this procedure.

**DNA extraction.** Bacterial DNA was extracted as described previously using a technique involving mechanical cell lysis with bead-beating regimens [32]. The extracted DNA was purified using the High Pure Polymerase Chain Reaction (PCR) Template Preparation Kit (Roche Diagnostics) following the manufacturer's instructions.

### 16S rRNA gene sequencing and data processing

PCR targeting the V3–V4 region of the bacterial 16S rRNA gene was performed using Ex Taq Hot Start (Takara Bio Inc.) for 35 cycles. The specific universal primer pairs 341 F (5'-CCTACGGGNGGCWGCAG) and 805 R (5'-GACTACHVGGGTATCTAATCC) were used in this study. PCR products were purified using SPRISelect beads (Beckman-Coulter Inc., California, USA). The amplified DNA was quantified using the ONEdsDNA System (Promega, Madison, WI, USA) and a Quantus fluorometer (Promega). The PCR amplicon libraries were prepared by pooling approximately equal amounts of amplified DNA and sequencing on an Illumina MiSeq platform (Illumina, San Diego, USA) using a 2 × 300 v3 600-cycle kit (Illumina) following the manufacturer's instructions.

### Data processing

Illumina MiSeq fastq raw reads were analysed using the QIIME 2 platform (version 2019.10) [33]. The sequences were demultiplexed using the DADA 2 programme [34]. Amplicon sequence variants obtained using DADA 2, which were more accurate than the traditional operational classification units (OTUs), were assigned through feature-classifier classify-sklearn and SILVA database (version 138.1) [35]. Diversity analysis was performed using the QIIME diversity core metrics phylogenetic method [32].

### Quantitative PCR

Absolute quantification using quantitative PCR (qPCR) was performed to investigate whether the species used in LBPs (*C. butyricum*) increased in the intestinal tract [36]. The following primer sets were utilised: total

bacteria, 5'-CGGYCCAGACTCTACGGG-3', and 5'-TTACCGCGGCTGCTGG-CAC-3'; and *C. butyricum*, 5'-AGTGATTGTAGTAGACGAGCG-3' and 5'-CATGCGCCCTTTGTAGC-3'. The assay was conducted on a Thermal Cycler Dice Real-Time System II (Takara Bio, Shiga, Japan) using TB Green® Premix Ex Taq™ II (Takara Bio).

### Statistical analysis

All statistical analyses were performed using the R software (version 4.1.1). Differences in alpha diversity and qPCR copies between groups were determined using the Mann–Whitney *U* test without any correction. For comparing numerical values of diversity distances, the Mann–Whitney *U* test and Welch's *t*-test were used. Community composition was visualised using principal coordinate analysis (PCoA). PCoA was conducted on a comprehensive distance matrix encompassing the entire sample set. The significance of the groups in the community structure was tested using a permutational multivariate analysis of variance (PERMANOVA) with 9999 permutations. Spearman's rank correlation coefficient was used to analyse the correlation for the relative abundance of bacterial genera against the first two principal coordinates (PC), namely PC1 and PC2. To estimate unique microbial genera in both groups treated with CBM588 and those without CBM588, DESeq2 was utilised. This tool assumes that read counts follow a negative binomial distribution [37].

## RESULTS

### Patient cohort

The characteristics of the patient cohort are summarised in Fig. 1 and Supplementary Tables 1 and 2. The mean age of the 37 patients during HSCT was 44 years (range: 20–64 years). The study population comprised 15 females and 22 males; 13 patients (35.1%) experienced grade 0 aGVHD, whereas 24 patients (64.9%) developed mild-to-severe aGVHD (grades 1–4), with a median onset of 37 days post-transplantation. All patients received antibiotics before and after transplantation. Levofloxacin was administered orally to all patients as a prophylactic antimicrobial. During the neutropenic phase, cefepime, a fourth-generation cephalosporin, was administered to 15 patients (40.5%). Additionally, carbapenems, including biapenem, meropenem, or imipenem, were administered to 33 patients (89.2%). CBM588 was administered only to patients at Osaka University Hospital; therefore, 11 patients (29.7%) received CBM588, and 26 patients (70.3%) did not. The 1-year survival rates of patients who received preventive CBM588 administration and those who did not were 81.8% and 69.2%, respectively. The survival rate did not differ significantly between the groups.


### Dissimilarity of the bacterial community from that observed pre-HSCT

We demonstrated the fluctuations in community changes pre-HSCT and for each respective time point using the weighted UniFrac distance of beta diversity (Fig. 2). The greater the alterations in the microbiota, the more pronounced the distance. The temporal microbiome distance between the pre-HSCT and post-HSCT exhibited demonstrable augmentation from day 14 to day 21. A comparison between patients who developed aGVHD and those who did not reveal a discernible modification in the microbiota of patients with aGVHD at 14 days post-HSCT compared with that before HSCT (mean = 0.68; range in patients with aGVHD, 0.35–1.01).

Additionally, we investigated community changes with and without lower gastrointestinal GVHD development, which contributes a great deal to the loss of diversity, and with and without CBM588 administration, but no significant differences were detected (Fisher's exact test:  $p = 0.443$ ; chi-square test:  $p = 0.474$ ) in this cohort (Supplementary Fig. 1).

### Association of the microbiota with aGVHD after aHSCT

The microbiota of patients who developed aGVHD were compared with those who did not. The two groups showed no significant



**Fig. 1** A selected sub-cohort of patients who underwent HSCT at two university hospitals was evaluated. The black circles represent observations taken over time. Periods of CBM588 administration are highlighted with blue lines. The right side of the chart presents additional data, including the onset of aGVHD, its severity grading, post-HSCT mortality dates (De), and the details of the preparatory conditioning regimen, MAC or (RIC). aGVHD Acute graft-versus-host disease, HSCT Haematopoietic stem cell transplantation, CBM588 *Clostridium butyricum* MIYAIRI 588, MAC Myeloablative, RIC Reduced-intensity conditioning.

differences in alpha diversity at any of the sampling time points (data not shown). Conversely, PCoA based on the weighted UniFrac distance revealed significantly different taxonomic structures at 14 days post-HSCT between patients with aGVHD and those without aGVHD (Fig. 3a and Supplementary Fig. 2). Notably, the PCoA plots for patients who developed aGVHD were concentrated below 0.0 for PC1 and 0.0 for PC2. A correlation analysis of bacterial abundance with PC1 and PC2 was performed (Fig. 3b). The bacterial taxonomic structure of patients who developed aGVHD was characterised by a strong negative correlation with PC1 for the genus *Bacteroides* ( $r = -0.852$ ) and a weak positive correlation with PC2 for the genus *Enterococcus* ( $r = 0.555$ ).


#### Impact of CBM588 consumption on the gut microbiota in allo-HSCT recipients

HSCT conditioning regimens are known to alter the gut microbiota [38]. Initially, we tracked the variations in alpha diversity from baseline (before the conditioning regimen) to day 35 between patients who received CBM588 and those who did not (Fig. 4a). As anticipated, the median alpha diversity of patients who did not


receive CBM588 declined gradually from 3.64 before transplantation to 2.03 after transplantation, with the peak decline observed on day 21. Conversely, among patients who received CBM588, the median alpha diversity remained consistent from baseline to day 21, ranging from 4.82 to 4.12. A two-dimensional representation of the unweighted UniFrac distance matrix was constructed using PCoA (Fig. 4b). A statistically significant divergence in the classification structure from 7 to 21 days was observed between the group that received CBM588 and the group that did not (PERMANOVA;  $p < 0.05$ ). Moreover, 16S metagenomic analysis provides reliable identification at the phylum to genus level but shows limited resolution at the species level [39]. Therefore, using qPCR, which is highly quantitative at the bacterial species level, we confirmed that *C. butyricum* outgrowth, the primary component, occurred only in the CBM588 treatment group (Supplementary Fig. 3).

#### Temporal changes in the dominant bacteria with CBM588 administration

Since *Bacteroides* and *Enterococcus* were abundant on day 14, the temporal variations in the abundance of these two bacterial



**Fig. 2** Boxplots depicting the variation in the weighted UniFrac distance between the pre- and post-HSCT microbiome at each time point, where Day -7 represents the pre-HSCT state. The asterisks indicate significant differences in distance values between patients who developed aGVHD post-HSCT and those who did not. These differences were assessed using the Mann-Whitney  $U$  test ( $p \leq 0.05$ ). HSCT Haematopoietic stem cell transplantation, aGVHD Acute graft-versus-host disease.



**Fig. 3** Structural changes in the intestinal microbiota and abundance of major bacterial groups in GVHD cases. **a** PCoA using weighted UniFrac distances highlighting the differences in the microbiome community structure at day 14 between individuals who developed aGVHD of grade I or higher and those who did not. **b** Heatmap showing the  $r$  values for the relative abundance of bacterial genera plotted against the first two principal coordinate values (PC1 and PC2). PCoA Principal coordinate analysis, aGVHD Acute graft-versus-host disease,  $r$  values, Correlation coefficients.

genera were investigated (Fig. 5). The results indicated that the genus *Enterococcus* was more abundant in the microbiota of patients who developed aGVHD after day 14, whereas the genus *Bacteroides* was more prevalent among patients with aGVHD not only on day 14 but throughout the entire period from pre-HSCT to post-HSCT. The swimmer plot illustrates on a patient-by-patient basis whether CBM588 was administered or not (indicated by the blue line). Remarkably, patients who received CBM588 for prophylaxis exhibited a lower relative abundance of genus *Bacteroides* throughout the observed period. For instance, patients with O63 demonstrated low levels of genus *Bacteroides* at all observed periods, even if the patient had developed GVHD.

To capture the dominated community state type, all samples were subjected to cluster analysis, ignoring the time series. The Ward linkage hierarchical clustering method, which utilises a weighted UniFrac metric, was used. According to the segmented phylogenetic tree, four clusters were generated (Supplementary Fig. 4). Cluster 1 was characterised by the phylum Firmicutes, with a preponderance of the genus *Enterococcus*; Cluster 2 was characterised by the phylum Firmicutes, with the prevalence of the genera *Blautia* and *Ruminococcus*; Cluster 3 was typified by the phylum Bacteroidetes, dominated by the genus *Bacteroides*; and Cluster 4 exhibited a mixed microbiome consisting of both phyla


Firmicutes and Bacteroidetes. We focused on days 7, 14, and 21 when post-transplant variability was high (Supplementary Fig. 5). According to the results of our cluster analysis, Cluster 4 consistently dominated the group that received CBM588, with proportions at each time point being 50.0%, 60.0%, and 42.9%, respectively. In contrast, in the group that did not receive CBM588, Cluster 3, represented by *Bacteroides*, accounted for 27.3%, 30.0%, and 43.5%, respectively.

We used DESeq2 to identify significantly different ASVs. Consistent with the cluster analysis results, we observed a significant elevation in genus *Enterococcus* levels in patients who did not receive CBM588 during the 7-day post-HSCT period ( $p < 0.05$  and log2 fold change = 5.55). Additionally, patients who did not receive CBM588 exhibited higher levels of the genus *Bacteroides* on day 21 post-transplant ( $p < 0.05$  and log2 fold change = 3.59).

## DISCUSSION

Numerous studies have examined the link between gut microbiota and post-HSCT outcomes. Our initial report highlights the potential of using a single bacterium, CBM588, to intervene and modulate the gut microbiota after HSCT.






**Fig. 4** *Clostridium butyricum* MIYAIRI 588 administration preserves faecal microbiota diversity in the early post-transplant period. **a** Figure representing the alpha diversity of the faecal microbiota in the following two groups during the early post-transplant period: the CBM588 and no-administration groups (Control). Asterisks highlight significant differences in the Shannon indices of the microbiome between two groups, as determined using the Mann–Whitney  $U$  test ( $*p \leq 0.05$ ,  $**p \leq 0.01$ ). **b** PCoA based on the unweighted UniFrac distance of the microbiome over time. Statistical calculations were performed using the Adonis test and involved 999 permutations. PcoA Principal coordinate analysis, CBM588 *Clostridium butyricum* MIYAIRI 588.

Previous studies have reported an association between dysbiosis and acute GVHD [40, 41]. As reported by Kusakabe et al., the sequential analysis of changes in the gut microbiota over time revealed that patients with large fluctuations in their microbiota had a poor prognosis [12]. To prove this, we compared the robustness of the microbiota of patients who developed aGVHD with that of patients who did not develop aGVHD by comparing the beta diversity distance matrix between the pre-HSCT and post-HSCT samples. Our results showed that at 14 days post-HSCT, patients who developed aGVHD had greater microbiota dissimilarity from pre-HSCT than those without aGVHD, suggesting that intervention and stabilisation of the gut microbiota before and early post-HSCT could help protect against GVHD.

In the early post-aHSCT period, patients who developed aGVHD exhibited lower microbial diversity [42–44]. These studies indicate a heightened risk of aGVHD-related complications associated with reduced bacterial diversity. Our study, based on the weighted UniFrac distance, revealed that patients who developed aGVHD had a significantly different microbiota composition compared to those who did not at 14 days post-HSCT. Therefore, changes in the composition of the gut microbiota may affect the host's immune response and contribute to GVHD development. The combination of a correlation analysis of the composition of PCoA and microbiota with a focus on bacteria showed that the abundance

of the genera *Bacteroides* and *Enterococcus* characterised the microbiota of the aGVHD group. Consistent with our findings, *Enterococcus* is reportedly associated with worsened GVHD [43, 45]. However, some studies have reported that the genus *Bacteroides* is abundant in non-GVHD cases [8], and others have reported expansion of the genus *Bacteroides* in studies of children with HSCT recipients and GVHD mouse models [46, 47]. Differences in temporal dynamics, recipient age, and host species may be responsible for these discrepancies in results among the studies. This heterogeneity can be resolved by higher-resolution species-level analyses.

In patients undergoing HSCT, the appropriate use of prophylactic antibiotics to control the intestinal environment while limiting the development of bacterial infections of intestinal origin is complicated [48]. Consequently, these patients tend to show reduced diversity of intestinal bacteria, resulting in a less diverse microbial community in comparison with the pre-transplant levels [49, 50]. In our study, the intestinal microenvironments of patients without CBM588 treatment consistently showed decreased bacterial diversity. In contrast, the alpha diversity of the patients receiving CBM588 treatment remained unchanged from the initial baseline, and the beta diversity of their overall bacterial structure also showed no significant changes. Oral administration of the probiotic *Lactobacillus plantarum* is safe and feasible in children and adolescents undergoing HSCT [51]. However, the genus



**Fig. 5** Swimmer plots illustrate the relative abundance of two bacterial genera, *Bacteroides* (left) and *Enterococcus* (right), in individual patients at each time point. The size of the circles corresponds to the relative abundance of each genus. The presence or absence of GVHD is differentiated by the upper and lower boxes, respectively, whereas the presence or absence of CBM588 is indicated by a blue line. CBM588 *Clostridium butyricum* MIYAIRI 588, GVHD Graft-versus-host disease.

*Lactobacillus* is sensitive to quinolone antibiotics, which are widely used for intestinal sterilisation, making *Lactobacillus* reaching the intestine difficult when quinolones are administered adequately. In contrast, CBM588, a spore-forming bacterium, maintains high biostability in the gut, suggesting that CBM588 does not alter the overall gut microbiota, which may be disrupted following transplantation. Additionally, alpha diversity was compared between the two universities to address potential confounding factors. Significant differences were observed only 7 days before transplantation, with no notable differences afterwards. This indicates that variations in facilities do not significantly affect the microbiota post-transplantation.

This study demonstrated that the abundance of genera *Enterococcus* and *Bacteroides* contributes to GVHD development. Throughout the observation period, their consistent abundance was confirmed. The abundance of the genus *Bacteroides* was lower in patients who received CBM588 than in those who did not. Cluster analysis on days 7, 14, and 21 shortly after transplantation also revealed a noticeably lower proportion of *Bacteroides* and

*Enterococcus* in the CBM588-treated group. The gut microbiota of patients with haematological cancers is considerably different from that of healthy individuals [11, 12]. From these findings, by stabilising the microbiota, CBM588 could prevent the predominance of bacteria potentially associated with post-transplant prognosis.

A limitation of this study is that the sample size was not large enough to identify significant differences in the prognosis and outcomes with CBM588 administration. The small sample limited our ability to detect a significant difference between patients with and without lower gastrointestinal acute GVHD, as the onset of lower gastrointestinal GVHD occurred at or after day 21. Moreover, the evaluations on days 14 and 21 might have been preferentially influenced by the broad-spectrum antibiotics that almost all patients were using than by the lower gastrointestinal GVHD that they were about to develop. Thus, further prospective multicentre studies are needed to better characterise the variables affecting these changes and address the influence of microbiota-based therapeutics on allo-HSCT recipients. Moreover, given that some studies suggest that gastrointestinal GVHD is challenging to

diagnose solely based on clinical symptoms, [52, 53] a comprehensive approach, incorporating endoscopic and histological evaluations with microbiota assessment, should be employed.

In conclusion, our data support the findings of previous reports showing that variations in gut bacteria influence clinical outcomes, including GVHD development. Furthermore, this is the first study to show that the administration of a microbiota-based therapeutic agent, CBM588, minimises post-transplant microbial fluctuations. Collectively, our findings uncover longitudinal microbiota maintained using CBM588, an LBP, and provide new insights for future therapeutic strategies.

## DATA AVAILABILITY

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

## REFERENCES

- Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. *Cell*. 2012;148:1258–70.
- Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol*. 2021;19:55–71.
- Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. *Cell Res*. 2020;30:492–506.
- Alexander T, Greco R, Snowden JA. Hematopoietic stem cell transplantation for autoimmune disease. *Annu Rev Med*. 2021;72:215–28.
- Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. *Bone Marrow Transpl*. 2019;54:1525–52.
- Granot N, Storb R. History of hematopoietic cell transplantation: challenges and progress. *Haematologica*. 2020;105:2716–29.
- Alexander T, Snowden JA, Burman J, Chang HD, Del Papa N, Farge D, et al. Intestinal microbiome in hematopoietic stem cell transplantation for autoimmune diseases: considerations and perspectives on behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. *Front Oncol*. 2021;11:722436.
- Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, et al. Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. *Bone Marrow Transpl*. 2015;50:992–8.
- Holler E, Butzhammer P, Schmid K, Hundsruker C, Koestler J, Peter K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. *Biol Blood Marrow Transpl*. 2014;20:640–5.
- Papanicolas LE, Sims SK, Taylor SL, Miller SJ, Karapetis CS, Wesselingh SL, et al. Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome. *BMC Cancer*. 2021;21:591.
- Hino A, Fukushima K, Kusakabe S, Ueda T, Sudo T, Fujita J, et al. Prolonged gut microbial alterations in post-transplant survivors of allogeneic hematopoietic stem cell transplantation. *Br J Haematol*. 2023;201:725–37.
- Kusakabe S, Fukushima K, Maeda T, Motooka D, Nakamura S, Fujita J, et al. Pre- and post-serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation. *Br J Haematol*. 2020;188:438–49.
- Kusakabe S, Fukushima K, Yokota T, Hino A, Fujita J, Motooka D, et al. Enterococcus: a predictor of ravaged microbiota and poor prognosis after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transpl*. 2020;26:1028–33.
- Cordallat-Simmons M, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. *Exp Mol Med*. 2020;52:1397–406.
- Food and Drug Administration. Title of subordinate document. In: Early Clinical Trials with Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information Guidance for Industry. Royal Society of Chemistry. 2016. <https://www.fda.gov/files/> of subordinate document. Accessed 25 Feb 2024.
- O'Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. *Nat Microbiol*. 2017;2:17057.
- Zhang Y, Saint Fleur A, Feng H. The development of live biotherapeutics against *Clostridioides difficile* infection towards reconstituting gut microbiota. *Gut Microbes*. 2022;14:2052698.
- Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, et al. Effect of *Clostridium butyricum* on fecal flora in *Helicobacter pylori* eradication therapy. *World J Gastroenterol*. 2005;11:7520–4.
- Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. Prevention of antibiotic-associated diarrhea in children by *Clostridium butyricum* MIYAIRI. *Pediatr Int*. 2003;45:86–90.
- Hagihara M, Kuroki Y, Ariyoshi T, Higashi S, Fukuda K, Yamashita R, et al. *Clostridium butyricum* modulates the microbiome to protect intestinal barrier function in mice with antibiotic-induced dysbiosis. *iScience*. 2020;23:100772.
- Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. *Nat Med*. 2022;28:704–12.
- Gorshein E, Wei C, Ambrosy S, Budney S, Vivas J, Shenkerman A, et al. *Lactobacillus rhamnosus* GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation. *Clin Transplant*. 2017;31:e12947.
- Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. *Blood*. 2016;128:2083–8.
- Sharma A, Tilak T, Bakhshi S, Raina V, Kumar L, Chaudhary S, et al. *Lactobacillus brevis* CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation. *ESMO Open*. 2016;1:e000138.
- van Lier YF, de Groot PF, Nur E, Zeerleder SS, Nieuwdorp M, Blom B, et al. Fecal microbiota transplantation as safe and successful therapy for intestinal graft-versus-host disease. *Blood*. 2017;130:1986.
- Yoshifuji K, Inamoto K, Kiridoshi Y, Takeshita K, Sasajima S, Shiraishi Y, et al. Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation. *Blood Adv*. 2020;4:4607–17.
- Yu J, Sun H, Cao W, Han L, Song Y, Wan D, et al. Applications of gut microbiota in patients with hematopoietic stem-cell transplantation. *Exp Hematol Oncol*. 2020;9:35.
- Sandhu KS, Yang D, Mokhtari S, Dadwal SS, Pullarkat VA, Al Malki MM, et al. A randomized open label pilot study of *clostridium butyricum* miyairi 588 (CBM588) in recipients of allogeneic hematopoietic cell transplantation. *Blood*. 2021;138:334.
- Bacigalupo A, Ballen K, Rizzo D, Giral S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transpl*. 2009;15:1628–33.
- Giral S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. *Biol Blood Marrow Transpl*. 2009;15:367–9.
- Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. *Biol Blood Marrow Transpl*. 2016;22:4–10.
- de Boer R, Peters R, Gierveld S, Schuurman T, Kooistra-Smid M, Savelkoul P. Improved detection of microbial DNA after bead-beating before DNA isolation. *J Microbiol Methods*. 2010;80:209–11.
- Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Author correction: reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol*. 2019;37:1091.
- Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. *Nat Methods*. 2016;13:581–3.
- Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res*. 2013;41:D590–6.
- Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, et al. *Clostridium butyricum* therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. *Oncoimmunology*. 2022;11:2081010.
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. *Genome Biol*. 2014;15:550.
- Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. *Nat Rev Cancer*. 2018;18:283–95.
- Hildebrand F. Ultra-resolution Metagenomics: When Enough Is Not Enough. *mSystems*. 2021;6:e0088121.
- Ingham AC, Kielsen K, Mordhorst H, Ifversen M, Aarestrup FM, Muller KG, et al. Microbiota long-term dynamics and prediction of acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. *Microbiome*. 2021;9:148.
- Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, et al. Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. *Blood Adv*. 2020;4:1824–32.
- Hong T, Wang R, Wang X, Yang S, Wang W, Gao Q, et al. Interplay between the intestinal microbiota and acute graft-versus-host disease: experimental evidence and clinical significance. *Front Immunol*. 2021;12:644982.



43. Ilett EE, Jorgensen M, Noguera-Julian M, Norgaard JC, Daugaard G, Helleberg M, et al. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. *Blood Adv*. 2020;4:5797–809.
44. Lin D, Hu B, Li P, Zhao Y, Xu Y, Wu D. Roles of the intestinal microbiota and microbial metabolites in acute GVHD. *Exp Hematol Oncol*. 2021;10:49.
45. Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, et al. Lactose drives *Enterococcus* expansion to promote graft-versus-host disease. *Science*. 2019;366:1143–9.
46. Biagi E, Zama D, Rampelli S, Turroni S, Brigidi P, Consolandi C, et al. Early gut microbiota signature of aGVHD in children given allogeneic hematopoietic cell transplantation for hematological disorders. *BMC Med Genomics*. 2019;12:49.
47. Heimesaat MM, Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. *Gut*. 2010;59:1079–87.
48. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. *Biol Blood Marrow Transpl*. 2009;15:1143–238.
49. Jimenez-Jorge S, Labrador-Herrera G, Rosso-Fernandez CM, Rodriguez-Torres N, Pachon-Ibanez ME, Smani Y, et al. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multi-centre OptimBioma study. *BMJ Open*. 2020;10:e034570.
50. Romick-Rosendale LE, Haslam DB, Lane A, Denson L, Lake K, Wilkey A, et al. Antibiotic exposure and reduced short chain fatty acid production after hematopoietic stem cell transplant. *Biol Blood Marrow Transpl*. 2018;24:2418–24.
51. Ladas EJ, Bhatia M, Chen L, Sandler E, Petrovic A, Berman DM, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. *Bone Marrow Transpl*. 2016;51:262–6.
52. Kim ES, Kwon Y, Choe YH, Kim MJ, Yoo KH. Impact of the histologic grade of acute gastrointestinal graft-versus-host disease on outcomes in pediatric patients treated with allogeneic hematopoietic stem cell transplantation. *Front Med*. 2023;10:1231066.
53. Tarantino G, Saraceni F, Mancini G, Poiani M, Maroni L, Goteri G, et al. Gastrointestinal complications after allogeneic hematopoietic stem cell transplant: a multidisciplinary approach with early endoscopic evaluation. *Clin Hematol Int*. 2021;3:161–8.

## ACKNOWLEDGEMENTS

We would like to thank Seiya Higashi, Central Research Institute, and Miyarisan Pharmaceutical Co., Ltd. for providing support with 16S rRNA sequence data processing.

## AUTHOR CONTRIBUTIONS

KF and MO designed the study; HK performed the sequencing analysis; KF and HK contributed to manuscript preparation; KF and MO managed the clinical data; and SK

and AH performed the data evaluation. KO and AH revised the manuscript critically. MT, KT, MM, KA, and HN supported the experimental design. All authors approved the submitted and final versions of the manuscript.

## FUNDING

Open Access funding provided by Osaka University.

## COMPETING INTERESTS

HK, KO, AH, and MT are employees of Miyarisan Pharmaceutical Co., Ltd. KT and NH received research funding from Miyarisan Pharmaceutical Co., Ltd.

## ADDITIONAL INFORMATION

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41409-024-02250-1>.

**Correspondence** and requests for materials should be addressed to Kentaro Fukushima.

**Reprints and permission information** is available at <http://www.nature.com/reprints>

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024